Contributor Content

An Early-Stage Hair-Loss Trial Opens A Cohort Just For Women

Absci is testing the safety and tolerability of an investigational treatment that targets the prolactin receptor.

Written by Kara Markley
Credit: Brasileira

Hair-loss research and treatment have historically focused on men and the biology of androgen-related hair loss. Although pattern hair loss is common in women, treatment options remain narrow. Today, only two drugs are FDA-approved for pattern hair loss: minoxidil and finasteride. But finasteride is approved for men, not women. Once women begin noticing gradual thinning on their scalp or along the center part of their hair, what can be done?

One company exploring a new approach to pattern hair loss in women is Absci. The company recently announced the launch of a women-only cohort as part of its ongoing Phase 1/2a trial for pattern hair loss.

Absci, a biotechnology company, is developing an investigational treatment called ABS-201. The Australian-based Phase 1/2a HEADLINE trial is a randomized, double-blind, placebo-controlled study testing an investigational injectable called ABS-201. It remains experimental and has not yet been established as safe and effective as a treatment for pattern hair loss. However, the company shared that the early-stage trial is primarily designed to examine the drug’s safety, tolerability, and how it behaves in the body, with hair-growth measures included as exploratory outcomes.

What The HEADLINE Trial Is Testing

The HEADLINE study is randomized, double-blind, and placebo-controlled, meaning neither participants nor researchers know during the trial who receives the investigational drug and who receives placebo. According to Absci, the study is set to include over 200 healthy adult volunteers across multiple cohorts with a focus on safety and tolerability. The experimental injectable is still in early clinical development, in a Phase 1/2a trial.

A Phase 1 trial is primarily designed to give researchers an early look at a drug’s safety and how it behaves in the body. These studies can also provide early signals that a treatment may be having an effect. After a Phase 1 trial ends, larger, later-stage Phase 2 and 3 trials are needed to better understand how well the treatment works, including how long any benefits may last and what risks may emerge with broader use.

Researchers are also examining pharmacokinetics, or how the drug moves through the body and interacts with its biological targets. For ABS-201, they are measuring changes in hair count, hair width, and hair pigmentation within a defined area of the scalp after treatment.

A Different Target

Most discussion of pattern hair loss has centered on hormones called androgens and DHT. Finasteride, approved by the FDA for male-pattern hair loss in 1997, works by blocking an enzyme involved in the conversion of testosterone to DHT.

Absci is developing ABS-201 around a different target: the prolactin receptor. Researchers have been investigating prolactin’s role in hair growth and hair loss for more than two decades. Prolactin is a hormone involved in a range of biological processes, and studies have found that human hair follicles produce prolactin and contain its receptor. In laboratory studies using human hair-follicle tissue, researchers have found that prolactin can influence the hair-growth cycle, including promoting the transition from the growth phase to the regression phase.

Still, the biology of prolactin and hair regrowth is not fully established in humans. Absci’s data on prolactin signalling on hair regrowth is preclinical, done on scalp models and animal models. The ongoing clinical trial will provide early data on how ABS-201 performs in people.

The HEADLINE trial is currently recruiting participants in Australia, including study locations in Brisbane, Sydney and Melbourne.

This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.

BDG Media newsroom and editorial staff were not involved in the creation of this content.